logo

EVAX

Evaxion·NASDAQ
--
--(--)
--
--(--)

EVAX fundamentals

Evaxion (EVAX) expects to report earnings on May 27, 2025, with estimated revenue of -- (YoY 0.00%), and EPS at -- (YoY 0.00%).
Revenue estimate / YoY
--
0.00%
EPS estimate / YoY
--
0.00%
Report date
May 27, 2025
EVAX Earnings Call Summary for Q1,2025
  • Merck Option Exercise Catalyst: Potential $10M H2 2025 milestone for EVX-B2/B3 compounds.
  • EVX-01 Immunogenicity: 80% target immune response rate, CD4 T-cell dominance, and CD8 response in half of patients.
  • Financial Strength: $17.8M cash (mid-2026 runway) and $10.3M equity, meeting NASDAQ requirements.
  • Pipeline Momentum: ERV vaccine lead selection in H2, first infectious disease candidate shortlisted.
  • Market Risk: Macro uncertainty delays 2025 deal execution, though two-deal target remains intact.
EPS
Revenue

Revenue & Expenses

EVAX has released its 2025 Q3 earnings report, with revenue of 7.49M, reflecting a YoY change of 148.33%, and net profit of 4.62M, showing a YoY change of 338.66%. The Sankey diagram below clearly presents EVAX's revenue sources and cost distribution.

Key Indicators

Evaxion (EVAX) key financial stats and ratios, covering profitability, financial health, and leverage.
Evaxion (EVAX)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Evaxion (EVAX)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Evaxion (EVAX)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Evaxion (EVAX) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Evaxion (EVAX) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield